GlassScriptPhysician profile
Jose C Ortiz
NPI 1134157522
$3,212.93
in general payments reported to CMS, 2019-2025
26 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $42.67 · 2022: $14.23 · 2023: $23.28 · 2024: $55.62 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.18 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $396.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $386.19 | 2019 | |
| Novo Nordisk INC | $332.38 | 2019 | |
| Amgen INC. | $308.05 | 2019 | |
| Amarin Pharma, INC. | $185.19 | 2019 | |
| Abbvie INC. | $162.42 | 2019-2022 | |
| Lilly USA, LLC | $126.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $125.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $122.18 | 2019 | |
| Glaxosmithkline, LLC. | $118.60 | 2019 | |
| Abbott Laboratories | $116.28 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $109.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.50 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $65.31 | 2019 | |
| Merck Sharp & Dohme LLC | $64.16 | 2019 | |
| Allergan, INC. | $62.98 | 2019 | |
| Horizon Therapeutics Plc | $57.24 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $37.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.00 | 2024 | Ultomiris |
| Janssen Biotech, INC. | $27.13 | 2019 | |
| Pfizer INC. | $25.62 | 2024 | |
| Ironwood Pharmaceuticals, INC | $23.86 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.28 | 2023 | |
| Scilex Pharmaceuticals INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.